GW Pharmaceuticals PLC (GWPH) Stock Rating Reaffirmed by Cantor Fitzgerald
GW Pharmaceuticals PLC (NASDAQ:GWPH)‘s stock had its “buy” rating reiterated by Cantor Fitzgerald in a report issued on Monday. They presently have a $208.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 81.23% from the company’s previous close.
The analysts wrote, “Tonight (11/20), the American Epilepsy Society (AES) published the abstracts for the upcoming annual meeting in early December.””
A number of other equities analysts have also issued reports on GWPH. Zacks Investment Research lowered shares of GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Maxim Group set a $135.00 target price on shares of GW Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Monday, August 7th. Leerink Swann reaffirmed an “outperform” rating and set a $160.00 price target (down from $162.00) on shares of GW Pharmaceuticals PLC in a report on Thursday, August 10th. BidaskClub downgraded GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Finally, Evercore ISI assumed coverage on GW Pharmaceuticals PLC in a report on Wednesday, August 16th. They set an “outperform” rating and a $154.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $144.55.
Shares of GW Pharmaceuticals PLC (NASDAQ GWPH) traded down $1.11 on Monday, hitting $114.77. 414,820 shares of the stock were exchanged, compared to its average volume of 319,576. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.26 and a current ratio of 10.39. GW Pharmaceuticals PLC has a twelve month low of $92.65 and a twelve month high of $136.95.
WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/11/20/gw-pharmaceuticals-plc-gwph-stock-rating-reaffirmed-by-cantor-fitzgerald.html.
A number of institutional investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC acquired a new stake in GW Pharmaceuticals PLC in the third quarter valued at $254,000. Janney Montgomery Scott LLC acquired a new stake in GW Pharmaceuticals PLC in the third quarter valued at $650,000. Ladenburg Thalmann Financial Services Inc. lifted its holdings in GW Pharmaceuticals PLC by 49.5% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,887 shares of the biopharmaceutical company’s stock valued at $294,000 after acquiring an additional 956 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in GW Pharmaceuticals PLC by 1,403.7% in the third quarter. Cubist Systematic Strategies LLC now owns 4,511 shares of the biopharmaceutical company’s stock valued at $458,000 after acquiring an additional 4,211 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in GW Pharmaceuticals PLC by 19.2% in the third quarter. Point72 Asset Management L.P. now owns 158,343 shares of the biopharmaceutical company’s stock valued at $16,070,000 after acquiring an additional 25,543 shares during the period. 75.57% of the stock is owned by institutional investors.
GW Pharmaceuticals PLC Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.